Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J Drucker

Showing results (61-70 of 313) with videos related to

Pageof 32
Sort By:
Nature Cancer|January 16, 2026
Glucagon-like peptide-1 medicines and cancerJulian M Yabut, Daniel J Drucker
The Journal of Clinical Investigation|November 3, 2025
Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefitsChi Kin Wong, Daniel J Drucker
Best Practice & Research. Clinical Endocrinology & Metabolism|November 10, 2004
Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2Laurie L Baggio, Daniel J Drucker
Nature Reviews. Endocrinology|March 13, 2013
Emerging combinatorial hormone therapies for the treatment of obesity and T2DMSharon A Sadry, Daniel J Drucker
The Lancet. Diabetes & Endocrinology|April 28, 2018
Precision medicine in the management of type 2 diabetesAnna L Gloyn, Daniel J Drucker
Nature Reviews. Endocrinology|May 16, 2009
Incretin-based therapies for type 2 diabetes mellitusJulie A Lovshin, Daniel J Drucker
Diabetes|October 12, 2007
Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed miceBenjamin J Lamont, Daniel J Drucker
Molecular Metabolism|September 28, 2020
Glucagon-like peptide-1 receptor co-agonists for treating metabolic diseaseLaurie L Baggio, Daniel J Drucker
Nature Reviews. Endocrinology|April 9, 2015
Islet α cells and glucagon--critical regulators of energy homeostasisJonathan E Campbell, Daniel J Drucker
Immunity|October 4, 2025
Obesity, diabetes, and inflammation: Pathophysiology and clinical implicationsMarc Y Donath, Daniel J Drucker
Pageof 32

Showing results (61-70 of 313) with videos related to

Sort By:
Pageof 32
Nature Cancer|January 16, 2026
Glucagon-like peptide-1 medicines and cancerJulian M Yabut, Daniel J Drucker
The Journal of Clinical Investigation|November 3, 2025
Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefitsChi Kin Wong, Daniel J Drucker
Best Practice & Research. Clinical Endocrinology & Metabolism|November 10, 2004
Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2Laurie L Baggio, Daniel J Drucker
Nature Reviews. Endocrinology|March 13, 2013
Emerging combinatorial hormone therapies for the treatment of obesity and T2DMSharon A Sadry, Daniel J Drucker
The Lancet. Diabetes & Endocrinology|April 28, 2018
Precision medicine in the management of type 2 diabetesAnna L Gloyn, Daniel J Drucker
Nature Reviews. Endocrinology|May 16, 2009
Incretin-based therapies for type 2 diabetes mellitusJulie A Lovshin, Daniel J Drucker
Diabetes|October 12, 2007
Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed miceBenjamin J Lamont, Daniel J Drucker
Molecular Metabolism|September 28, 2020
Glucagon-like peptide-1 receptor co-agonists for treating metabolic diseaseLaurie L Baggio, Daniel J Drucker
Nature Reviews. Endocrinology|April 9, 2015
Islet α cells and glucagon--critical regulators of energy homeostasisJonathan E Campbell, Daniel J Drucker
Immunity|October 4, 2025
Obesity, diabetes, and inflammation: Pathophysiology and clinical implicationsMarc Y Donath, Daniel J Drucker
Pageof 32